Sign In
Buy QGEN
$37.56
+1.11 (+3.05%)
At Close: Jun 04, 2026
QGEN or ILMN: Which Is the Better Value Stock Right Now?
03:40pm, Monday, 25'th Apr 2022 Zacks Investment Research
QGEN vs. ILMN: Which Stock Is the Better Value Option?
QGEN or ILMN: Which Is the Better Value Stock Right Now?
12:47pm, Monday, 25'th Apr 2022
QGEN vs. ILMN: Which Stock Is the Better Value Option?
QIAGEN N.V. to release results for Q1 2022 and hold Webcast
12:45pm, Wednesday, 20'th Apr 2022
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to release results for Q1 2022 and hold Webcast
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
11:18am, Monday, 28'th Mar 2022
Investors are optimistic about QIAGEN's (QGEN) recent expansion in test menu and strategic collaborations.
QIAGEN (QGEN) QuantiFeron Hits New Sales Landmark in TB Testing
02:10pm, Thursday, 24'th Mar 2022 Zacks Investment Research
According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.
Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?
12:10pm, Monday, 21'st Mar 2022 Zacks Investment Research
Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price
Illumina (ILMN) Debuts TSO Comprehensive Test in Europe
02:30pm, Friday, 18'th Mar 2022 Zacks Investment Research
Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.
Illumina (ILMN) Invests in Seven Additional Genomics Startups
02:08pm, Friday, 18'th Mar 2022 Zacks Investment Research
Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.
Blackstone acquires 49% stake in One Manhattan West from Brookfield, QIA (NYSE:BX)
08:39pm, Monday, 14'th Mar 2022 Seeking Alpha
Blackstone (BX) Real Estate has acquired a 49% stake in One Manhattan West from Brookfield Asset Management (BAM) and Qatar Investment Authority in a deal that values the office building…
Why Is Qiagen (QGEN) Down 11.3% Since Last Earnings Report?
04:30pm, Thursday, 10'th Mar 2022 Zacks Investment Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Qiagen (QGEN) Down 11.3% Since Last Earnings Report?
12:47pm, Thursday, 10'th Mar 2022
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Precision Medicine Global Market Report 2022
09:50am, Thursday, 03'rd Mar 2022 GlobeNewswire
Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services. Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services.
Singular Genomics inks partnerships with Agilent and Qiagen for sequencing platform
02:10pm, Monday, 28'th Feb 2022 Seeking Alpha
La Jolla, California-based life sciences company, Singular Genomics Systems (OMIC), announced two separate partnerships with Agilent Technologies (A) and COVID-19 test maker QIAGEN…
Element Biosciences Partners with QIAGEN to Validate a Selection of QIAseq Targeted Library Construction Chemistries on Elements AVITI System
01:00pm, Tuesday, 22'nd Feb 2022 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Element Biosciences Partners with QIAGEN to Validate a Selection of QIAseq Targeted Library Construction Chemistries on Elements AVITI System
Global Epigenetics Market to Reach USD 3.0 Billion by 2028 - Powered by Increased Investment in the Healthcare AR and VR Vantage Market Research
08:49am, Monday, 21'st Feb 2022 Benzinga
WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Epigenetics Market finds that increasing cancer rates may further expediting market growth. Primarily driven by increasing research activity and funding for Epigenetics, the total Global Epigenetics Market is estimated to reach USD 3.0 Billion by 2028. The market stood at a revenue of USD 0.8 Billion in the year 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, the increasing personalized medication, and target therapy are also anticipated to augment the growth of the Global Epigenetics Market, states Vantage Market Research, in a report, titled " Epigenetics Market by Product (Instruments, Reagents & Kits, Others), by Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases), by Technology (Methylation, Acetylation, Phosphorylation, Other Technologies), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".
